Live Breaking News & Updates on Safety Results

Stay updated with breaking news from Safety results. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting

TEPEZZA Phase 4 trial results to be shared in an oral presentation on Saturday, June 17 at 3:30 p.m. CT

Two patients will share their real-world experience living with TED and being. | June 5, 2023 ....

Olmsted County , United States , Jeffreyw Sherman , Malini Gupta , Duke University Health System , European Group On Grave Orbitopathy , Drug Administration , Endocrine Society , Horizon Therapeutics , Thyroid Eye Disease , Safety Results , Placebo Controlled Multicenter Trial , Oral Presentation , Multicenter Trial , Hearing Related Issues Associated , Grave Disease , Hearing Related Adverse Events , Teprotumumab Oncology Clinical Trials , Teprotumumab Pooled Efficacy , European Study Sites Participating , Inactive Thyroid Eye Disease Patient Journey , Eye Disease , Early Diagnosis , Duke University Health , Treatment Experience , Exhibit Hall ,

Zentalis Announces Presentation of Positive Phase 1b Data

Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of 50.0% and mPFS of 7.4 months in combination. ....

San Diego , United States , New York , Kimberly Blackwell , Premalh Thaker , Joyce Liu , Emily White , Danielle Cantey , Division Of Gynecologic Oncology , Zentalis Pharmaceuticals , Gynecological Oncology Clinical Research , Dana Farber Cancer Institute , Washington University School Of Medicine , Solebury Strategic Communications , Exchange Commission , Pharmaceuticals Inc , Chief Executive Officer , Safety Results , Frequent Grade , Associate Chief , Clinical Research , Gynecologic Oncology , Dana Farber Cancer , Washington University School , Board Number , Discussion Session Date ,

Zentalis Pharmaceuticals (ZNTL) Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy

Zentalis Pharmaceuticals (ZNTL) Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New York , United States , San Diego , Joyce Liu , Premalh Thaker , Danielle Canteyevoke Canale , Kimberly Blackwell , Pharmaceuticals Inc , Dana Farber Cancer Institute , Exchange Commission , Zentalis Pharmaceuticals , Emily Whitesolebury Strategic Communications , Division Of Gynecologic Oncology , Gynecological Oncology Clinical Research , Washington University School Of Medicine , Chief Executive Officer , Safety Results , Frequent Grade , Associate Chief , Clinical Research , Gynecologic Oncology , Dana Farber Cancer , Washington University School , Session Title , Gynecologic Cancersession Date , Board Number ,

HARMONY BIOSCIENCES TO PRESENT NEW WAKIX® (PITOLISANT) SAFETY AND EFFICACY DATA AT SLEEP 2023 ANNUAL MEETING

Late-breaking Phase 2 proof-of-concept study in Prader-Willi syndrome accepted for poster presentation
PLYMOUTH MEETING, Pa., May 10, 2023 /PRNewswire/ Harmony Biosciences Holdings, Inc. , a. | May 10, 2023 ....

United States , Kumar Budur , Luis Sanay , Drug Administration , Exchange Commission , Paragon Biosciences , Prnewswire Harmony Biosciences Holdings Inc , Late Breaking Phase , Biosciences Holdings , Annual Meeting , Associated Professional Sleep Societies , Chief Medical Officer , Meaningful Improvements , Pooled Analysis , Randomized Clinical Trials , Presentation Date , Board Number , Breast Milk , Healthy Lactating Women , Pregnancy Registry , Pitolisant Exposure , Pregnant Women , Their Offspring , Safety Results , Placebo Controlled Proof , Signal Detection Study ,

Phase 2 Results of Pitolisant in Prader-Willi Syndrome

Harmony Biosciences will present new efficacy data from a phase 2 study evaluating pitolisant in patients with Prader-Willi syndrome. ....

Kumar Budur , Drug Administration , Harmony Biosciences Holdings Inc , Meaningful Improvements , Pooled Analysis , Randomized Clinical Trials , Presentation Date , Board Number , Safety Results , Placebo Controlled Proof , Signal Detection Study , Prader Willi Syndrome ,